PharPoint acknowledges Rare Disease Day, February 29th 2020

This Saturday, February 29th is Rare Disease Day 2020⁠ — a day made to raise awareness for the 300 million people living with a rare disease around the world. PharPoint Research, an award-winning CRO with extensive experience supporting rare disease clinical research, is proud to support Rare Disease Day. Our team is relentless in helping our clients so that they may advance the research and approval of breakthrough treatments today and every day.

About Rare Disease Day 2020

About the Day: Rare Disease Day is organized each year by EURORDIS Rare Diseases Europe. The day began in 2008, and has grown in size every year since its inception. Most recently, 2019’s rare disease day events included participants from over 100 different countries and regions. Rare Disease Day 2020 focuses around the key message, “Rare is many. Rare is strong. Rare is proud!”

About Rare Diseases: There are approximately 6,000+ rare diseases that are chronic, progressive, degenerative, disabling and frequently life threatening. Unfortunately, between 90-95% of these diseases have no FDA approved treatments, and many go undiagnosed. Rare disease clinical research studies pose unique challenges in project management, site selection, patient enrollment, and retention.

About PharPoint Research

PharPoint Research is an award-winning, client focused contract research organization (CRO) with extensive experience within rare disease. PharPoint supports clients of all sizes in the pharmaceutical and biotechnology industries, offering services in clinical operations, project management, biostatistics and statistical programming, data management, and strategic clinical trial consulting.

With a 95% client retention rate, PharPoint Research offeres clients attentive, consultative expertise across a range of therapeutic areas including rare disease.

Looking for a Rare Disease CRO for your upcoming study?
Since 2007, PharPoint has supported over 100 rare disease trials, including approved rare disease NDA/MAA submissions.